Financial Performance - The Company reported a net loss from operations of $5.7 million for the nine months ended September 30, 2025, with cash on hand of $6.9 million and marketable securities of $3.1 million[255]. - As of September 30, 2025, the Company had working capital of $4.6 million and stockholders' equity of $14.3 million, including an accumulated deficit of $137.6 million[255]. - Net loss for the three months ended September 30, 2025, was $2,811,388, compared to a net loss of $1,929,391 for the same period in 2024, representing a 46% increase in losses[272]. - The company has not generated any revenue from product sales and does not expect to do so in the near future[261]. - Other income (expense), net for the three months ended September 30, 2025, was $1,022,736, compared to $103,752 in 2024, indicating a significant increase in expenses[285]. - As of September 30, 2025, the company had cash on hand of $6,904,185 and marketable securities of $3,091,772, with a net loss attributable to stockholders of $8,424,093 for the nine months ended[309]. - Net cash provided by financing activities was $9,351,879 for the nine months ended September 30, 2025, compared to $13,926,528 in 2024, reflecting a decrease of 32.5%[316]. - Cash flows used in operating activities were $5,865,877 for the nine months ended September 30, 2025, compared to $6,855,523 in 2024, indicating a decrease of 14.4%[310]. - The company recorded a gain of $244,000 related to the change in fair value of derivative liabilities for the nine months ended September 30, 2025, compared to a loss of $11,000 in 2024[307]. - Other income, net of expenses, totaled $400,783 for the nine months ended September 30, 2025, a significant improvement from a net expense of $13,315,173 in 2024[305]. Strategic Focus and Development - The Company has shifted its focus to energy-efficient blockchain and cryptocurrency infrastructure through quantum-class laser-based computing, specifically the qc-LPU100, which aims to outperform traditional GPUs and QPUs in speed and efficiency[236]. - Over the next twelve months, the Company anticipates finalizing qc-LPU100 prototypes and initiating pilot testing with select AI and DePin Token users[239]. - The Company plans to generate revenue through direct sales, leasing, and licensing of qc-LPU100 units, with potential revenue streams including hardware sales and subscription-based access[240]. - The Company is evaluating the potential divestiture of its pharmaceutical platforms, Isomyosamine and Supera-CBD, to maximize value and fund its new strategic focus[237]. - The company expects operating expenses to increase as development activities for the qc-LPU100 advance[263]. - The company is evaluating strategic alternatives for its historical therapeutic platforms, including potential divestiture or licensing transactions[258]. - The Company agreed to acquire 100% of LPU's membership interests, with consideration including shares convertible into 747,362 shares of Common Stock[384]. - The Company will pay up to $8,500,000 in non-recurring engineering fees to Lightsolver for development work related to cryptocurrency mining applications[394]. Capital Structure and Financing - The Company closed a $7.0 million private placement of Series H Preferred Stock to fund its strategic shift towards technology adaptation[238]. - The Company has increased its authorized shares of Common Stock from 250 million to 1.25 billion to support its capital needs[244]. - The Company received net proceeds of approximately $5.0 million from the Series F-1 Private Placement, intended for general corporate purposes[338]. - The Company received net proceeds of approximately $8.9 million from the Series G Private Placement, intended for general corporate purposes[351]. - The Series F-1 and Series G Preferred Stock holders are entitled to vote on an as-converted basis, with voting calculated at a conversion price of $2.253 per share[342][355]. - The Company engaged placement agents for the Series H Private Placement, agreeing to pay a cash fee of 4% of gross proceeds and issue warrants equal to 4% of the shares underlying the securities issued[371][372]. - The Company has engaged Palladium as a financial advisor, agreeing to a monthly retainer of $15,000 and issuing 15,433 shares of Common Stock[387]. Expenses and Cost Management - Total operating expenses for the three months ended September 30, 2025, were $1,788,652, a decrease of 2% from $1,825,639 in the same period of 2024[272]. - General and administrative expenses for the nine months ended September 30, 2025, were $2,703,815, a decrease of 14% from $3,149,041 in 2024[290]. - Research and development expenses for the three months ended September 30, 2025, totaled $356,352, down 50% from $707,747 in 2024, primarily due to the suspension of the Phase 2b study of Isomyosamine[281][282]. - Total research and development expenses rose to $2,775,337 for the nine months ended September 30, 2025, up from $2,307,789 in 2024, marking a 20.3% increase[300]. - Development program costs increased by $837,474 during the nine months ended September 30, 2025, compared to the same period in 2024, primarily due to drug product production and consulting fees[301]. - Stock-based compensation decreased significantly by $781,264 during the nine months ended September 30, 2025, compared to the same period in 2024[297]. - Franchise tax expenses for Delaware increased to $200,050 for the nine months ended September 30, 2025, compared to $40,548 for the same period in 2024, representing a 392% increase[298]. - The company incurred franchise tax expenses of $200,050 for the three months ended September 30, 2025, compared to $0 in 2024[280]. Regulatory and Compliance Issues - The Company faces regulatory challenges related to cryptocurrency, hardware, and emerging quantum technology, which may impact its operations and compliance[242]. - The Company has not experienced any changes in internal control over financial reporting that materially affect its financial reporting[402].

Core Points - TNF Pharmaceuticals, Inc. has changed its corporate name to Q/C Technologies, Inc. [1] - The company will begin trading under the new ticker symbol "QCLS" on the Nasdaq Capital Market starting September 25, 2025 [1] - Until the name change takes effect, the company's common stock will continue to trade under the current ticker symbol "TNFA" [1] - The new name reflects the company's recent strategic direction [1]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____________ to ____________ Commission File Number: 001-36268 TNF Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) | Delaware | 22-2983783 | ...

Financial Position - As of March 31, 2025, the company had cash on hand of $73,244 and marketable securities totaling $5,801,531, with a net loss attributable to stockholders of $1,938,239 for the three months ended March 31, 2025[237]. - The company has an accumulated deficit of $131,076,525 as of March 31, 2025[237]. - Cash on hand decreased from $225,655 in Q1 2024 to $73,244 in Q1 2025, while marketable securities increased from $1,509,358 to $5,805,331[272]. - Net cash used in operating activities was $2,640,240 in Q1 2025, compared to $1,757,199 in Q1 2024[274]. Operating Performance - The company reported a net loss of $1,124,743 for the three months ended March 31, 2025, compared to a net loss of $9,800,041 for the same period in 2024[254]. - The company incurred a net loss attributable to stockholders of $1,938,239 in Q1 2025, compared to a net loss of $11,001,908 in Q1 2024[272]. - Total operating expenses for the three months ended March 31, 2025, were $2,471,834, a decrease from $2,784,623 in the same period of 2024, with research and development expenses increasing to $1,545,513 from $1,198,938[254]. Research and Development - The company is focused on developing Isomyosamine and Supera-CBD, with significant anticipated expenses related to clinical trials and commercialization efforts[240]. - Total research and development expenses increased from $1,198,938 in Q1 2024 to $1,545,513 in Q1 2025, an increase of approximately 29%[262]. - Development program costs rose by $470,883, from $888,538 in Q1 2024 to $1,359,421 in Q1 2025, related to drug product production and clinical trials[263]. - The company anticipates significant increases in operating expenses as it progresses through clinical trials for its product candidates[244]. Funding and Capital Structure - The company plans to seek additional funding through private equity or debt financings to support its operations and growth strategy[237]. - The Company received net proceeds of approximately $5.0 million from the Series F-1 Private Placement, intended for general corporate purposes[295]. - The Company received net proceeds of approximately $8.9 million from the Series G Private Placement, intended for general corporate purposes[309]. - The Series F Conversion Price was adjusted to $0.364 per share as of March 31, 2025, reflecting anti-dilution provisions[280]. Shareholder and Stock Information - The company received a Nasdaq deficiency letter on March 17, 2025, indicating it did not meet the minimum bid price requirement of $1.00 per share[238]. - The Company is required to redeem the Series F Preferred Shares in 12 equal monthly installments starting July 1, 2023, with payments either in cash or shares of Common Stock valued at the lower of the Series F Conversion Price or a Floor Price of $6.60[282]. - The holders of the Series F Preferred Shares are entitled to dividends of 10% per annum, compounded monthly, increasing to 15% per annum upon a Triggering Event[288]. - The Series G Preferred Shares will accrue dividends at a rate of 15% per annum during a Triggering Event, with total dividends recorded of $559,032 for the year ended December 31, 2024[313]. Administrative and Personnel Expenses - Total administrative expenses decreased from $1,068,320 in Q1 2024 to $841,685 in Q1 2025, a reduction of approximately 21.3%[256]. - Personnel costs decreased by $79,440, from $190,071 in Q1 2024 to $110,631 in Q1 2025, reflecting staff reductions[257]. - Professional services costs decreased by $179,034, from $416,365 in Q1 2024 to $237,331 in Q1 2025, primarily due to non-recurring expenses[258]. - Stock market and investor relations costs increased by $73,605, from $104,547 in Q1 2024 to $178,152 in Q1 2025[259]. Accounting and Estimates - Critical accounting estimates include fair-market value of preferred stock and stock-based compensation, which may materially affect financial statements[326][328]. - The Company’s financial position and results are influenced by accounting policies, which are detailed in the consolidated financial statements[327]. - Management's estimates are based on historical experience and known trends, with potential for material changes in future results[328]. - There have been no material changes to critical accounting estimates since the last Annual Report filed on April 11, 2025[329].

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____________ to ____________ Commission file number: 001-36268 TNF Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 22-2983783 (S ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____________ to ____________ Commission File Number: 001-36268 TNF Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) | --- | |- ...